Philadelphia Trust Co. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,922 shares of the biopharmaceutical company’s stock after purchasing an additional 1,025 shares during the quarter. Philadelphia Trust Co.’s holdings in Pfizer were worth $1,506,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Lumature Wealth Partners LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $228,000. Godshalk Welsh Capital Management Inc. raised its stake in shares of Pfizer by 2.6% during the 4th quarter. Godshalk Welsh Capital Management Inc. now owns 29,078 shares of the biopharmaceutical company’s stock valued at $1,070,000 after purchasing an additional 725 shares during the period. Greenleaf Trust increased its stake in Pfizer by 8.0% in the 4th quarter. Greenleaf Trust now owns 257,516 shares of the biopharmaceutical company’s stock worth $9,479,000 after acquiring an additional 19,114 shares during the last quarter. Greenhouse Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $101,000. Finally, Bowen Hanes & Co. Inc. boosted its position in shares of Pfizer by 8.8% during the 4th quarter. Bowen Hanes & Co. Inc. now owns 90,122 shares of the biopharmaceutical company’s stock valued at $3,317,000 after acquiring an additional 7,305 shares during the last quarter. Institutional investors own 67.36% of the company’s stock.

Shares of PFE opened at $34.26 on Tuesday. The firm has a market cap of $190.43 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 2.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $43.08. The firm has a 50 day moving average price of $35.94 and a 200-day moving average price of $37.10.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the previous year, the firm earned $0.55 earnings per share. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.89 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 4.55%. This is an increase from Pfizer’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Thursday, January 28th. Pfizer’s payout ratio is presently 52.88%.

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada set a $42.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Monday, January 4th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Tuesday, November 10th. They set a “market perform” rating and a $42.00 target price for the company. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $37.00 target price for the company in a research report on Thursday, October 29th. Barclays lifted their target price on shares of Pfizer from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Friday, December 4th. Finally, SVB Leerink dropped their target price on shares of Pfizer from $44.00 to $40.00 and set a “market perform” rating for the company in a research report on Wednesday, February 3rd. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.38.

Pfizer Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Article: What is a Roth IRA?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.